Viking Global Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Viking Global Investors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-201,756	Closed	-$36.5M	–	76
2015 Q2	$36.5M	Buy	+201,756	New	+$34.8M	0.14%	52
2015 Q1	–	Sell	-390,271	Closed	-$72.2M	–	72
2014 Q4	$72.2M	Sell	390,271 -1,808,180	-82%	-$335M	0.33%	51
2014 Q3	$365M	Buy	2,198,451 +192,359	+10%	+$31.6M	1.46%	30
2014 Q2	$313M	Buy	2,006,092 +169,434	+9%	+$26.8M	1.37%	24
2014 Q1	$279M	Sell	1,836,658 -1,040,350	-36%	-$165M	1.17%	30
2013 Q4	$382M	Sell	2,877,008 -577,632	-17%	-$69.3M	1.78%	24
2013 Q3	$401M	Sell	3,454,640 -2,090,309	-38%	-$229M	2.22%	21
2013 Q2	$511M	Buy	+5,544,949	New	+$534M	2.84%	13

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Viking Global Investors's ALXN Position: Q3 2015 in Review

Viking Global Investors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2015, closing a stake of 201,756 shares — an estimated $36.5M sold.

Viking Global Investors first reported a position in ALXN in Q2 2013 and held it in 8 quarters. The position peaked at $511M in Q2 2013. 514 funds tracked by Wall St. Rank hold ALXN as of Q3 2015.

Viking Global Investors reported no remaining Alexion Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Viking Global Investors sold 201,756 Alexion Pharmaceuticals shares in Q3 2015, an estimated $36.5M.
Viking Global Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Viking Global Investors's Alexion Pharmaceuticals position peaked at $511M in Q2 2013.
514 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2015.

Based on Viking Global Investors's 13F filing for Q3 2015, filed 16 Nov 2015.